Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

University of Rostock35 enrolled

Overview

BDNF has been linked to the pathogenesis of airway hyperresponsiveness in asthma. In this trial, the impact of a treatment with salmeterol and salmeterol / fluticasone on BDNF concentrations will be assessed in patients with asthma. The investigators hypothesize that salmeterol impacts on BDNF concentrations in patients with asthma.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Allergic Asthma

Interventions

Salmeterol and Salmeterol / FluticasoneDRUG

Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years, a physician's diagnosis of allergic asthma * A documented sensitization to aero-allergens (pollen, animal hair, or house dust mite) * A pre-bronchodilator forced expiratory volume in the first second (FEV1) \> 80 % of the predicted value (% predicted), a provocative concentration of histamine causing a 20 % fall in FEV1 (PC20) of \< 8 mg histamine / ml Exclusion Criteria: * No regular treatment (only short-acting inhalers on demand were allowed) * No history of or evidence for any other chronic disease than asthma * No history of smoking, absence of any signs or symptoms of an infection

Locations (1)

University of Rostock

Rostock, Germany

Outcomes

Primary Outcomes

BDNF concentrations in serum, platelets and plasma

Time frame: 2006 - 2007

Secondary Outcomes

Airway hyperresponsiveness

Time frame: 2006 - 2007

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.